Medical News

RSS

United Therapeutics’ revenues increase by $24.4 million in second quarter 2015

United Therapeutics Corporation today announced its financial results for the second quarter ended June 30, 2015. "Orenitram sales grew nearly 300% as compared to the second quarter of 2014 when the product was first launched," said Roger Jeffs, Ph.D., United Therapeutics' President and Co-Chief Executive Officer.

28 Jul 2015

Researchers at Sydney’s Centenary Institute fight against hepatitis infection

Today is World Hepatitis Day. 400 million people around the world are currently living with hepatitis B or C. Each year, we see around 1.4 million people die from viral hepatitis. Researchers at Sydney’s Centenary Institute are working hard to change this.

28 Jul 2015

New finding could help change pharmaceutical treatment of neurodegenerative diseases

Diseases like Alzheimer's are caused when proteins aggregate and clump together. In a world first, EPFL scientists have successfully distinguished between the disease-causing aggregation forms of proteins.

28 Jul 2015

World Hepatitis Alliance partners with WHO to raise awareness on viral hepatitis

The World Hepatitis Alliance, and its supporters today asks the public, the hepatitis community and governments to raise awareness of the 4000 people who die from viral hepatitis every day.

28 Jul 2015

Research brief provides clinical validation of LOXO-101 Phase 1 trial for treatment of TRK fusion cancer

The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development.

28 Jul 2015

Despite efforts to improve stroke treatment, delays in emergency transport still prevalent

Despite efforts to close the time gap between symptom onset and stroke treatment - including improvements in public education, 911 dispatch operations, pre-hospital detection and triage, hospital stroke system development, and stroke unit management - a new study presented today at the Society of NeuroInterventional Surgery (SNIS) 12th Annual Meeting suggests that delays in emergency transport are still prevalent and that improvements are needed to ensure patients can be treated within the optimal time window.

28 Jul 2015

German life sciences entrepreneurs granted option to develop Aeterna Zentaris’ oral allogenic tumor vaccine technology

Aeterna Zentaris Inc. today announced that it has granted to German life sciences entrepreneurs with a proven track-record of funding the development and commercialization of biotechnology, an option to license the Company's live recombinant oral allogenic tumor vaccine technology, including AEZS-120, the most advanced product candidate for prostate cancer which is ready to enter a Phase 1 clinical trial.

28 Jul 2015

VolitionRx selects Global Specimen Solutions to support U.S. market entry of NuQ colorectal cancer tests

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that it has engaged the services of a specialty specimen management clinical research organization, Global Specimen Solutions, Inc., to support initial U.S. market entry of its NuQ colorectal cancer tests.

28 Jul 2015

Egalet declares pricing of underwritten public offering of common stock

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a public offering price of $11.25 per share.

28 Jul 2015

One in four people with implanted defibrillators experiences improvements in heart function

A Johns Hopkins-led study of outcomes among 1,200 people with implanted defibrillators -- devices intended to prevent sudden cardiac death from abnormal heart rhythms -- shows that within a few years of implantation, one in four experienced improvements in heart function substantial enough to put them over the clinical threshold that qualified them to get a defibrillator in the first place.

28 Jul 2015

Centene reports strong financial results for Q2 2015

Centene Corporation today announced its financial results for the quarter ended June 30, 2015. The following discussions, with the exception of cash flow information, are in the context of continuing operations.

28 Jul 2015

Europe has increasing prevalence of fungal resistance, warns ESCMID

The European Society of Clinical Microbiology and Infectious Disease – an organization that explores the risks and best practices in infectious disease – is imploring global healthcare professionals and bodies to take a more active role in the growing problem of fungal resistance.

28 Jul 2015

Champions Oncology's revenue increases 32% to $3.2 million in fourth quarter 2015

Champions Oncology, Inc., engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the year ended April 30, 2015.

28 Jul 2015

ESSA Pharma receives final approval to start trading on Toronto Stock Exchange

ESSA Pharma Inc. is pleased to announce that it has received final approval for its common shares to be listed and commence trading on the Toronto Stock Exchange.

28 Jul 2015

Hoaglund Enterprises awarded contract to evaluate Avian Flu affected equipment

Hoaglund Enterprises, Inc.,dba Asset Equipment Appraisals & Brokerage, a leading Nationally Certified Appraisal company is pleased to announce that they have been awarded a contract to appraise Avian Flu affected equipment that cannot be disinfected on infected farms by the USDA.

28 Jul 2015

Study findings could lead to new ways to tailor therapies for cancer

By studying the yeast used in beer- and bread-making, researchers at the University of Pittsburgh School of Medicine have uncovered the mechanism by which ancient proteins repair DNA damage and how their dysfunction could lead to the development of tumors.

28 Jul 2015

LMU researchers reveal role of mutations in development of Ewing's sarcoma

Researchers from Ludwig-Maximilians-Universitaet in Munich have elucidated at the molecular level how an otherwise innocuous inherited mutation that is quite common in European populations interacts with a spontaneous somatic mutation to promote the development of Ewing's sarcoma.

28 Jul 2015

Research brief describes enrollment of first patient with TRK fusion cancer in LOXO-101 Phase 1 trial

The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase (TRK) fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development.

28 Jul 2015

Lidocaine benefits breast cancer survivors who experience pain during intercourse

Scientists at Oregon Health & Science University report that breast cancer survivors who experience pain during sexual intercourse, a common side effect of breast cancer treatment, may achieve comfort when liquid lidocaine is applied strategically to prevent pain.

28 Jul 2015

CRINONE (progesterone gel) approved in nine new EU countries

Juniper Pharmaceuticals, Inc., a women's health specialty pharmaceutical company, today announced that the regulatory bodies of nine new European Union (EU) countries, including Poland and France, have granted marketing authorization to CRINONE (progesterone gel) under the mutual-recognition procedure (MRP).

28 Jul 2015

Medical News

United Therapeutics’ revenues increase by $24.4 million in second quarter 2015

Researchers at Sydney’s Centenary Institute fight against hepatitis infection

New finding could help change pharmaceutical treatment of neurodegenerative diseases

World Hepatitis Alliance partners with WHO to raise awareness on viral hepatitis

Research brief provides clinical validation of LOXO-101 Phase 1 trial for treatment of TRK fusion cancer

Despite efforts to improve stroke treatment, delays in emergency transport still prevalent

German life sciences entrepreneurs granted option to develop Aeterna Zentaris’ oral allogenic tumor vaccine technology

VolitionRx selects Global Specimen Solutions to support U.S. market entry of NuQ colorectal cancer tests

Egalet declares pricing of underwritten public offering of common stock

One in four people with implanted defibrillators experiences improvements in heart function

Centene reports strong financial results for Q2 2015

Europe has increasing prevalence of fungal resistance, warns ESCMID

Champions Oncology's revenue increases 32% to $3.2 million in fourth quarter 2015

ESSA Pharma receives final approval to start trading on Toronto Stock Exchange

Hoaglund Enterprises awarded contract to evaluate Avian Flu affected equipment

Study findings could lead to new ways to tailor therapies for cancer

LMU researchers reveal role of mutations in development of Ewing's sarcoma

Research brief describes enrollment of first patient with TRK fusion cancer in LOXO-101 Phase 1 trial

Lidocaine benefits breast cancer survivors who experience pain during intercourse

CRINONE (progesterone gel) approved in nine new EU countries

How real-time off-gas analysis improves fermentation process control

Advancing Drug Safety Assessment With AI, Predictive Modeling, and Human-Relevant Data

AI-powered analytics and experimental validation

Latest News